251 related articles for article (PubMed ID: 17325166)
1. Melanocortin 1 receptor is expressed by uveal malignant melanoma and can be considered a new target for diagnosis and immunotherapy.
López MN; Pereda C; Ramírez M; Mendoza-Naranjo A; Serrano A; Ferreira A; Poblete R; Kalergis AM; Kiessling R; Salazar-Onfray F
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1219-27. PubMed ID: 17325166
[TBL] [Abstract][Full Text] [Related]
2. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
3. Expression of cancer-testis antigens (MAGE-A1, MAGE-A3/6, MAGE-A4, MAGE-C1 and NY-ESO-1) in primary human uveal and conjunctival melanoma.
Errington JA; Conway RM; Walsh-Conway N; Browning J; Freyer C; Cebon J; Madigan MC
Br J Ophthalmol; 2012 Mar; 96(3):451-8. PubMed ID: 22190731
[TBL] [Abstract][Full Text] [Related]
4. Cripto-1 expression in uveal melanoma: an immunohistochemical study.
Mallikarjuna K; Vaijayanthi P; Krishnakumar S
Exp Eye Res; 2007 Jun; 84(6):1060-6. PubMed ID: 17412323
[TBL] [Abstract][Full Text] [Related]
5. Uveal and cutaneous melanoma: shared expression characteristics of melanoma-associated antigens.
van Dinten LC; Pul N; van Nieuwpoort AF; Out CJ; Jager MJ; van den Elsen PJ
Invest Ophthalmol Vis Sci; 2005 Jan; 46(1):24-30. PubMed ID: 15623750
[TBL] [Abstract][Full Text] [Related]
6. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):1-8. PubMed ID: 11773005
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions.
de Vries TJ; Fourkour A; Wobbes T; Verkroost G; Ruiter DJ; van Muijen GN
Cancer Res; 1997 Aug; 57(15):3223-9. PubMed ID: 9242453
[TBL] [Abstract][Full Text] [Related]
8. Concordant loss of melanoma differentiation antigens in synchronous and asynchronous melanoma metastases: implications for immunotherapy.
Trefzer U; Hofmann M; Reinke S; Guo YJ; Audring H; Spagnoli G; Sterry W
Melanoma Res; 2006 Apr; 16(2):137-45. PubMed ID: 16567969
[TBL] [Abstract][Full Text] [Related]
9. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma.
de Vries TJ; Trancikova D; Ruiter DJ; van Muijen GN
Br J Cancer; 1998 Nov; 78(9):1156-61. PubMed ID: 9820172
[TBL] [Abstract][Full Text] [Related]
10. Integrin expression in uveal melanoma differs from cutaneous melanoma.
ten Berge PJ; Danen EH; van Muijen GN; Jager MJ; Ruiter DJ
Invest Ophthalmol Vis Sci; 1993 Dec; 34(13):3635-40. PubMed ID: 8258522
[TBL] [Abstract][Full Text] [Related]
11. Role of epidermal growth factor receptor in the metastasis of intraocular melanomas.
Ma D; Niederkorn JY
Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1067-75. PubMed ID: 9620065
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of fourteen proteins between uveal melanoma from patients who subsequently developed distant metastases versus those who did Not.
Linge A; Kennedy S; O'Flynn D; Beatty S; Moriarty P; Henry M; Clynes M; Larkin A; Meleady P
Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4634-43. PubMed ID: 22570344
[TBL] [Abstract][Full Text] [Related]
13. Human leukocyte antigen class I expression. Marker of poor prognosis in uveal melanoma.
Blom DJ; Luyten GP; Mooy C; Kerkvliet S; Zwinderman AH; Jager MJ
Invest Ophthalmol Vis Sci; 1997 Aug; 38(9):1865-72. PubMed ID: 9286277
[TBL] [Abstract][Full Text] [Related]
14. Proteomics of uveal melanomas suggests HSP-27 as a possible surrogate marker of chromosome 3 loss.
Coupland SE; Vorum H; Mandal N; Kalirai H; Honoré B; Urbak SF; Lake SL; Dopierala J; Damato B
Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):12-20. PubMed ID: 19643972
[TBL] [Abstract][Full Text] [Related]
15. A new Mr 55,000 surface protein implicated in melanoma progression: association with a metastatic phenotype.
Boukerche H; Baril P; Tabone E; Bérard F; Sanhadji K; Balme B; Wolf F; Perrot H; Thomas L
Cancer Res; 2000 Oct; 60(20):5848-56. PubMed ID: 11059782
[TBL] [Abstract][Full Text] [Related]
16. Expression and distribution of MMPs and TIMPs in human uveal melanoma.
Lai K; Conway RM; Crouch R; Jager MJ; Madigan MC
Exp Eye Res; 2008 Jun; 86(6):936-41. PubMed ID: 18423620
[TBL] [Abstract][Full Text] [Related]
17. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA.
Sundram U; Harvell JD; Rouse RV; Natkunam Y
Mod Pathol; 2003 Aug; 16(8):802-10. PubMed ID: 12920225
[TBL] [Abstract][Full Text] [Related]
18. Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.
Khatib N; Pe'er J; Ortenberg R; Schachter J; Frenkel S; Markel G; Amer R
Invest Ophthalmol Vis Sci; 2011 Dec; 52(13):9368-72. PubMed ID: 22039239
[TBL] [Abstract][Full Text] [Related]
19. Uveal melanoma cell staining for CD34 and assessment of tumor vascularity.
Chen X; Maniotis AJ; Majumdar D; Pe'er J; Folberg R
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2533-9. PubMed ID: 12147581
[TBL] [Abstract][Full Text] [Related]
20. In vitro targeting of NG2 antigen by 213Bi-9.2.27 alpha-immunoconjugate induces cytotoxicity in human uveal melanoma cells.
Li Y; Wang J; Rizvi SM; Jager MJ; Conway RM; Billson FA; Allen BJ; Madigan MC
Invest Ophthalmol Vis Sci; 2005 Dec; 46(12):4365-71. PubMed ID: 16303921
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
